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Abstract 
Background 
Next generation sequencing technology, coupled with population genetic 
databases, have made broad genetic evaluation relatively inexpensive and 
widely available. Our objective was to assess the prevalence of potentially 
damaging cancer and cardiac gene variants in advanced non-ischemic 
cardiomyopathy patients. 
Methods 
Explanted human heart tissue procured at LVAD placement was obtained from 
the University of Nebraska Medical Center Heart Tissue Bank. Genomic DNA 
was isolated from tissues and amplified by PCR using targeted ampliseq primer 
pools from an inherited disease panel. Individual libraries were amplified by 
emulsion PCR on Ion Sphere particles and sequencing was performed on a PGM 
sequencer (Ion torrent) using the Ion 316 chip. The Ion Torrent browser suite was 
used to map the reads and call the variants. The identified single nucleotide 
polymorphisms, insertions, and deletions were then annotated and characterized 
with ANNOVAR. Non-synonymous mutations with a population frequency of less 
than or equal to 1% were identified and analyzed utilizing an open source 
integrative genomics viewer. Amino acid substitution effects on protein function 
were determined by a bioinformatics algorithm. Myocardial recovery was defined 
as an improvement in EF to greater than 45% at three months post implant. 
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Results 
Our sample population included 12 males and 2 females with an average age of 
49 and an average EF at presentation of 17%. Damaging cardiac gene variants 
were present in 11/14 patients. Only 1 of the 11 patients with damaging cardiac 
gene variants improved their ejection fraction to greater than 45% post LVAD. 
Two of the 2 patients without mutations improved their ejection fraction to greater 
than 45%, p-value=.04. Nine of the 14 patients in this population had damaging 
oncogene mutations. 
Conclusions 
Damaging variants in cancer and cardiac genes are common in end-stage non-
ischemic cardiomyopathy patients undergoing LVAD placement. Genetic 
variation likely contributes to disease progression and cancer risk. 
Keywords 
Ventricular assist device; genetics; LVAD; cardiomyopathy; oncology; 
sequencing 
Introduction 
 Heart failure is a complex disease process.   Patients are at increased risk for 
sudden cardiac death, pump failure, and, interestingly, cancer. (1)  Genetic 
variation likely contributes to cancer risk, progressive cardiac remodeling, 
arrhythmias, as well as poor response to both medical and mechanical 
interventions.  Population based sequencing studies utilizing mutation databases 
suggest that healthy individuals on average carry about 400 damaging genetic 
variants and 2 disease causing mutations.(2)   The prevalence of deleterious or 
disease causing mutations in patients undergoing left-ventricular assist device 
placement is unknown.  Non-ischemic cardiomyopathies may be caused by 
variants in at least 30 genes.  Cancer has also been associated with variation in 
numerous genes as well.  These are likely underestimates as disease causing 
variants are often rare and disease allele discovery continues.  It is estimated 
that the current human population contains billions of mutations that cause or 
modify disease.(3)  Understanding the impact of genetic variation within the 
advanced heart failure populations will hopefully improve patient selection for 
advanced heart failure interventions and improve clinical outcomes.   
Ventricular assist devices have become standard of care for advanced heart 
failure patients, both as a bridge to transplantation and as destination therapy.(4, 
5)  Clinical outcomes of patients with left ventricular assist devices are, however, 
difficult to predict utilizing demographic, laboratory, and echocardiographic risk 
scores.(6)  Patients who receive ventricular assist devices suffer from the most 
advanced heart failure, but have an immediate improvement in myocardial 
systolic and diastolic parameters.(7, 8)   These devices effectively improve 
hemodynamics, quality of life, and survival in appropriately selected 
individuals.(5, 9)  Despite these obvious benefits, myocardial recovery to the 
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degree that devices can be explanted is rare.(10, 11)  Right ventricular failure 
remains a problem with many of these patients.(12, 13)  Unloading the heart with 
mechanical cardiac support may contribute to progressive myocardial atrophy or 
these hearts may simply be unrecoverable due to underlying disease processes 
including genetic abrnomalities.(14-18)  Cardiac transplantation is a limited 
option for the majority of these patients, secondary to limitations in donor supply, 
and malignancy is a major problem in the advanced heart failure population post-
transplant.   
Next generation sequencing technologies involve parallel sequencing of millions 
of DNA fragments simultaneously allowing for whole genome or targeted 
sequencing of individuals.  Familial cardiomyopathies, rhythm disorders, and 
cancer all display high degrees of heterogeneity, necessitating the sequencing of 
the coding region of multiple genes.  Advances in sequencing technologies have 
made genetic testing faster, cheaper, and more readily available.  Bioinformatic 
algorithms have been used to describe the functional significance of these 
variants. These include annotating single nucleotide variants and 
insertions/deletions for their effects on genes, reporting their conservation levels, 
calculating their predicted functional importance scores, retrieving allele 
frequencies in public databases, and implementing a 'variants reduction' protocol 
to identify a subset of potentially deleterious variants/genes.  
Non-ischemic cardiomyopathy is a common and important cause of heart failure 
worldwide. It is the leading indication for cardiac transplantation or ventricular 
assist device placement.  The main aim of this study was to assess the 
prevalence of damaging or disease causing variants in cancer or cardiac genes 
in a cohort of advanced non-ischemic cardiomyopathy patients undergoing LVAD 
placement.     
Methods 
Myocardial tissue was obtained from the Nebraska Cardiovascular Biobank at 
the University of Nebraska Medical Center (UNMC).  These patients were 
undergoing LVAD implantation at the time of tissue procurement.  LVADs were 
implanted as bridge to transplantation or as destination therapy.  Patients were 
selected for non-ischemic dilated cardiomyopathies.  Cardiac function was 
determined at baseline and three month follow-up by echocardiography.   This 
study was approved by the IRB at UNMC.    
Next Generation Sequencing:  Genomic DNA was isolated from tissues and 
amplified by PCR using targeted ampliseq primer pools from an inherited disease 
panel.  Individual libraries were amplified by emulsion PCR on Ion Sphere 
particles and sequencing was performed on a PGM sequencer (Ion torrent) using 
the Ion 316 chip.  The Ion Torrent browser suite was used to map the reads and 
call the variants.  The identified single nucleotide polymorphisms, insertions, and 
deletions were then annotated and characterized with ANNOVAR. Non-
synonymous mutations with a population frequency of less than or equal to 1% 
were identified and analyzed utilizing an open source integrative genomics 
viewer.  Amino acid substitution effects on protein function were determined by a 
bioinformatics algorithm. Genomic DNA isolation kit utilized All prep DNA/RNA 
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mini kit from Qiagen, Valencia, CA.  Inherited disease panel primers, DNA library 
preparation kit, OT2 emulsion PCR kit and sequencing kit were purchased from 
Ion torrent from Life technology, Carlsbad, CA. 
 
Variant Classification:  According to the Association for Clinical Genetic Science 
recommendations, we utilized a stepwise approach to recording our variants, 
Figure 1.  We annotated our results to sort out synonymous gene mutations 
leaving only non-synonymous mutation results. In our next step of evaluation, we 
utilized ClinVar, an open database of greater than 30,000 mutations, to assess 
for documented or known pathogenic gene mutations.  If the variant was 
documented to be clearly pathogenic or clearly benign, we reported these results 
as such.  
 
 
 
 
Mutations that were novel or did not meet ClinVar criteria, as either clearly 
pathogenic or clearly benign, were investigated further.  Mutations fulfilling the 
following internationally recommended criteria were considered likely to be 
pathogenic: 1) non-synomynous variant causing an amino acid change in a 
residue that is highly conserved among species and predicted to significantly 
damage the protein structure or function, and 2) the variant was rare in control 
populations utilizing the 1000 Genomes Project,  the National Heart, Lung and 
Blood Institute Exome Sequencing Project and the Single Nucleotide 
Polymorphism Database with a cutoff allelic frequency of < 1%.  Co-segregation 
analysis was not performed as our study collected tissue in an anonymous 
fashion.  
 
Results  
 
Patient Characteristics:  Our sample population included 12 males and 2 females 
with an average age of 49 years and an average LVEF at presentation of 17%.  
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Baseline patient characteristics are shown in Table 1.   Damaging cardiac gene 
variants were present in 12/14 patients in Table 2.  Only 1 of the 12 patients with 
damaging cardiac gene variants improved their ejection fraction to greater than 
45% post LVAD.  Four of the 12 patients had the same damaging mutation in the 
SCN5A gene.  Two of the 2 patients without mutations improved their ejection 
fraction to greater than 45%, p-value=.04. 
 
 
 
 
 
Two of our patients had gene variants associated with ion channels, RYR2 and 
SCN5A.  SCN5A or sodium channel, voltage gated, type V, alpha subunit 
belongs to a family of genes that provide instructions for making sodium 
channels.  The phenotypic associations of this gene include Brugada syndrome, 
Romano-Ward syndrome and the sick-sinus syndrome.  The RYR2 gene is also 
termed ryanodine receptor 2 (cardiac).  This protein is responsible for the 
makeup of calcium ion channels.  Phenotypic associations include 
catecholaminergic polymorphic ventricular tachycardia, as well as 
arrhythmogenic right ventricular cardiomyopathy (ARVC). Other gene variants 
included those at MYH7, MYH6, DSG2, DSC2 and DES.  All are associated with 
the makeup of the sarcomere and cytoskeleton, and are associated with a range 
of cardiomyopathies including ARVD10, and various dilated cardiomyopathies.  
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Damaging oncogene mutations were present in 9 of the 14 patients in Table 3.  
These included the RET proto-oncogene, as well as NF1, a tumor suppressor 
gene. Other variants were identified in genes responsible for DNA repair. These 
include WRN, a gene that is responsible for an enzyme that can function as both 
a helicase and an exonuclease.  This gene has the ability to unwind DNA, 
remove damaged segments and repair it.  Phenotypic associations include 
multiple types of cancers.  It is also interesting to note that this gene can be 
subject to methylation, a process where chemical modification of a gene is 
acquired over time via the addition of methyl groups.  When the gene undergoes 
excessive methylation or hypermethylation, it is rendered non-functional.  Other 
DNA repair genes include the FANCG gene, as well as the MLH1 gene.  
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Discussion   
 
Our work suggests that damaging cardiac gene variants are highly prevalent in 
this advanced heart failure population.  In patients undergoing LVAD therapy for 
non-ischemic dilated cardiomyopathy, 86% have underlying genetic damage to 
cardiac genes.   Cardiomyopathy remains a leading etiology for cardiac 
transplantation as well as placement of left ventricular assist devices.   In 2012, 
over 50% of cardiac transplants were done for cardiomyopathies.   The 
cardiomyopathies are complex heterogeneous disorders.  Previous studies have 
suggested that between 20 and 48% of patients with idiopathic dilated 
cardiomyopathies have familial disorders.(19, 20) (21)  For dilated 
cardiomyopathies alone, mutations in over 40 different genes have been 
described.    Within each gene many different mutations may occur, hence many 
mutations are relatively rare or unique within a family.   Historically, 
cardiomyopathies have been classified and risk stratified according to clinical 
features.  Advances in genetic sequencing now allow for broad testing and better 
classification within large populations.   
 
While further studies are needed to characterize genetic interactions with clinical 
outcomes, our results suggest those patients with damaging cardiac gene 
variants have poor myocardial recovery with LVAD therapy.   Of interest is our 
observation that many of our patients have multiple cardiac or oncogenic 
mutations, which suggest a multiple hit hypothesis in development of dilated 
cardiomyopathy.  Utilizing genetic sequencing and bioinformatics algorithms, it 
may be feasible to identify poor responders to medical or device therapy earlier 
in their disease process.    Transitioning these patients more rapidly towards 
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mechanical support or transplantation may improve outcomes long term.   
Conversely, identifying patients who could recover sufficient cardiac function with 
LVAD therapy, with appropriate ancillary medical therapy, could decrease the 
need for cardiac transplantation and improve utilization of medical resources.   
Guideline directed medical therapy for heart failure may improve myocardial 
recovery but this therapy is not without risks and the majority of patients do not 
respond.   Genetic sequencing may further allow us to personalize heart failure 
treatment algorithms.  As an example, a high proportion of patients in this study 
had damaging mutations in SCN5A.  A positive response to Flecainide, a sodium 
channel blocker,  has been observed in cohorts with damaging SCN5A 
mutations.(22)  This is not a drug that we routinely use in the setting of advanced 
heart failure. 
Damaging oncongene variants are also highly prevalent in this advanced heart 
failure population.  Heart failure patients are at increased risk for developing 
cancer for reasons that are unclear.   Advanced heart failure patients who 
undergo cardiac transplant are also at high risk for developing cancer.  This may 
be related to inflammation, medications, or underlying genetic disorders.   Our 
results suggest that that this patient population may also have a high prevalence 
of damaging variants in oncogenes.  We may have an opportunity to “intervene” 
in our patient’s care earlier in both their cancer and cardiac disease processes.  
Cardio-Oncology is evolving as a specialty.  The main focus has been on the 
diagnosis and management of cardiovascular diseases in patients with cancer.   
Cancer surveillance guided by genetic testing could be equally as important in 
this population of patients with heart failure. 
  
Our study is not without limitations. This is a single center observational study.  
Our population was small in size and utilized targeted gene panels to sequence 
only genes previously associated with inherited diseases.   This was done in an 
effort to look for gene variants that have the best supporting evidence for disease 
association, but we may miss other gene variants in this process.  It is also of 
note that the concept of “variation” implies that there is variation from a reference 
genome, i.e., the human genome project.  Variation does not always translate to 
disease causation. Variants of uncertain significance are found every day and 
add to the expanding knowledge of the human genome.   
 
Conclusion  
 
Damaging cardiac gene variants are common in non-ischemic dilated 
cardiomyopathy patients with advanced heart failure. The presence of damaging 
gene variation likely portends a poor prognosis and non-response to both 
medical and mechanical interventions.  The absence of such mutation may 
predict response and possibly even recovery.  Damaging variation in oncogenes 
is also a common finding in this population. This may help explain the finding of 
increased cancer prevalence in advanced heart failure.  Larger, more controlled 
studies are needed to help guide therapeutic decisions and increase the 
precision of the care delivered to this most important population.  
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